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Abstract 
Background: Interstitial lung disease (ILD) and lung cancer are 
two of the most common respiratory diseases. The aim of this 
study was to demonstrate the prognostic significance of the 
presence of ILD in patients with small cell lung cancer (SCLC).  
Methods: All the patients with SCLC who were admitted to our 
hospitals over a 23-year period up to 2008 were retrospectively 
analyzed.   
Results: During the study period, 332 SCLC patients were 
consecutively admitted to our hospitals. Among them, 15 (4.5%) 
were diagnosed as having both SCLC and ILD. In univariate and 
multivariate analysis, female sex, early stage, good 
performance status, and chemotherapy were favorable prognostic 
factors. The presence of ILD was confirmed as an unfavorable 
prognostic factor.   
Conclusions: Existing ILD adversely affects the outcome of SCLC.  
When deciding whether to offer a standard therapy that may 
increase treatment-related mortality, the patient’s medical 
condition, including ILD, should be taken into consideration. 
 
Keywords: interstitial lung disease; survival; small cell lung 
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Introduction 
Lung cancer is still one of the most common fatal malignancies.1 
Despite the progress made in various therapeutic modalities, 
the overall outcome of patients with lung cancer, especially 
those with small cell lung cancer (SCLC), remains poor and has 
not decreased to a level with which we can be satisfied.2,3 
Cigarette smoking and occupational exposures are common 
contributors not only to SCLC but also to interstitial lung 
disease (ILD) such as idiopathic pulmonary fibrosis (IPF).4,5 
Collagen disease-associated pulmonary fibrosis (CDPF) and IPF 
are the most common ILDs. Irrespective of the etiology of ILD, 
the therapeutic approach to SCLC patients with ILD is very 
complex owing to high post-therapeutic pulmonary complications 
and mortality. However, the clinicopathological features of 
both limited and extensive SCLC patients with ILD have not been 
clarified, and the influence of the existence of ILD on survival 
in SCLC patients has not been well evaluated. In this study, 
therefore, we examined the prognostic significance of 
coexistent ILD in patients with SCLC. 
 
Patients and Methods 
All the patients with pathologically or cytologically proven 
SCLC who were admitted to Tsukuba University Hospital and 
Tsukuba Medical Center Hospital over a 23-year period up to 
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August 2008 were retrospectively analyzed. Patients were staged 
according to the staging system of the Veterans Administration 
Lung Cancer Study Group: limited stage (LD) or extensive stage 
(ED). Patients with LD-SCLC have involvement restricted to the 
ipsilateral hemithorax within a single radiation port. 
Extensive stage SCLC is defined as the presence of obvious 
metastatic disease. The records of these patients were studied 
to assess the indication of treatment and outcome. Pretreatment 
chest conventional or high-resolution computed tomography 
(HRCT) was evaluated in all cases to determine not only the 
extent of lung cancer but also the existence of ILD. 
Interstitial lung disease was diagnosed on the basis of medical 
history, physical examination, and abnormalities compatible 
with bilateral lung fibrosis detected on conventional CT or HRCT, 
such as peripheral reticular opacities.6 As in previous 
studies,6,7 this study included IPF and CDPF as ILD. We evaluated 
the number and seriousness of comorbid diseases using the 
Charlson index (CI) score.8 This study was approved by the 
institutional ethics committee of each hospital.   
We divided the SCLC patients into 2 groups: patients with ILD 
(ILD group) and those without ILD (non-ILD group). Statistical 
significance between the 2 groups was determined using the 
Mann-Whitney U test and chi-square test. The Kaplan–Meier 
method was used to assess survival curves and the log-rank test 
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to evaluate the statistical significance of differences between 
the 2 groups. The length of survival was defined as the interval 
in months from the date of the initial therapy or supportive 
care until the date of deaths or the date of last follow-up. 
The Cox proportional hazards model was used to study the effects 
of clinicopathological factors on survival.9 All statistical 
analyses were performed using SPSS 10.1 for Windows (SPSS, 
Chicago, IL, USA) and a probability value less than 0.05 was 
considered to be significant. 
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Results 
There were 332 patients with pathologically or cytologically 
proven SCLC. The characteristics of these patients are 
summarized in Table 1. There were 294 (88.6%) men and 38 women. 
Two hundred twenty-one (69.6%) patients were 65 years of age 
or older. There were 278 (83.7%) patients with good performance 
status (PS) (ECOG 0-1), and 159 (47.9%) patients with LD-SCLC.   
Among all the patients, 15 (4.5%) were diagnosed as having ILD. 
Table 2 shows the differences between the SCLC patients with 
ILD and those without ILD. In the 15 SCLC patients with ILD, 
14 were men, and 13 had good PS (PS 0-1). Thirteen patients 
received chemotherapy, but no patient with ILD had chest 
irradiation. There was no significant difference in proportion 
with regard to age, sex, PS, clinical stage, and treatment 
between the ILD group and non-ILD group (Table 2). There was 
no treatment-related death due to acute exacerbation of 
pneumonia in patients without ILD, but 1 patient with ILD had 
treatment-related death after the completion of sequential 
chemoradiotherapy. In addition, there was a difference between 
the ILD group and non-ILD group in the number of courses of 
chemotherapy performed. Fewer courses of chemotherapy were 
conducted in patients with ILD (median: 1 course; range: 1 - 
4 courses) than in those without ILD (median: 2 courses; range: 
1 - 6 courses)(P = 0.004). 
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In the univariate analysis, female sex, LD-SCLC, good PS (PS 
0-1), and chemotherapy were favorable prognostic factors (Table 
3). Figure 1 shows the survival curves of the patients in the 
ILD group and non-ILD group. Presence of ILD was an unfavorable 
prognostic factor (Table 3). However, age 65 years or younger, 
the number of comorbid diseases (2 or more), and the Charlson 
index (2 or more) were not prognostic (P = 0.4187, P = 0.1476, 
P = 0.2025, respectively). According to a multivariate Cox 
proportional hazards model, female sex, LD-SCLC, good PS (PS 
0-1), and chemotherapy were favorable prognostic factors. 
Presence of ILD was confirmed as an unfavorable prognostic 
factor in the multivariate analysis (Table 3). 
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Discussion 
Interstitial lung disease, such as IPF and CDPF, remains a 
devastating and progressive pulmonary disease characterized by 
alveolar destruction, excess matrix production, and varying 
levels of inflammation leading to impaired gas exchange.10 As 
patients with ILD have pulmonary functional impairment and poor 
cardiopulmonary reserve, many of them may not match the 
indications for standard therapies and may need palliative care. 
Moreover, ILD is associated with an increased risk of lung 
cancer, with a relative risk of 7.0 to 14.0 compared with the 
general population.11,12 On the other hand, only a few studies 
have shown the incidence of ILD in SCLC patients.13-15 Park et 
al showed that 12 (3.1%) out of 390 SCLC patients were diagnosed 
as having IPF.13 Kushibe reported that 33 (3.1%) out of 1063 
lung cancer patients had IPF.16 In the present study, we showed 
that 15 (4.5%) out of 332 SCLC patients were diagnosed as having 
IPF. This result was almost the same incidence of ILD in SCLC 
patients as those in previous studies,13,16 although the 
definition of ILD was different. 
Because of the design of clinical trials in which eligibility 
criteria preclude involvement of patients with impairment of 
organ function, many published studies have not shown the 
outcome of treatment of SCLC patients with comorbid disease such 
as ILD. As a result, there is little published information 
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regarding the results of treatment and prognostic factors in 
unselected groups of SCLC patients including those with both 
SCLC and ILD. Therefore, we evaluated the results of treatment 
and prognostic factors in unselected SCLC patients who were 
admitted to our 2 hospitals. In the present series of patients, 
we confirmed that female sex, LD-SCLC, and good PS were 
favorable prognostic factors for SCLC, as has been reported in 
a previous study.17 Additionally, we revealed that patients with 
ILD had worse overall survival than did those without, and 
existence of ILD was one of the unfavorable prognostic factors 
for survival in SCLC patients.   
It is very important to report why ILD worsened the prognosis 
of SCLC in our patients. We observed treatment-related death 
due to acute exacerbation of pneumonitis in 1 patient with ILD. 
Moreover, fewer courses of chemotherapy were conducted in the 
ILD group in this study. Eight of 13 patients in the ILD group 
had deterioration of PS after the first course of chemotherapy, 
and they did not continue with additional courses. Therefore, 
we supposed that fewer courses of chemotherapy in the ILD group 
resulted in worse survival.   
Some chemotherapeutic agents such as Adriamycin and CPT-11 are 
contraindicated for SCLC patients with ILD because of the 
development of respiratory failure due to worsening ILD.18,19 
Therefore, in many clinical trials, these SCLC patients were 
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excluded and there have been no apparent clinical data with 
regard to the treatment of SCLC patients with ILD. In addition, 
chest irradiation may accelerate pulmonary fibrosis inside as 
well as outside of the irradiation field, which causes 
deterioration of respiratory function and development of 
respiratory failure. Especially for LD-SCLC patients who have 
coexistent ILD, chemoradiotherapy is not indicated for the  
same reason that respiratory complication may ensue.20,21 
Post-therapeutic deterioration of pulmonary function 
necessitating mechanical ventilation and tracheostomy was also 
a cause of death and occurred more frequently in ILD patients 
than in non-ILD patients.6,7,13 These contraindications narrow 
the choice of the treatment and may have some relationship with 
the poor prognosis of SCLC patients with ILD.   
The limitations of this study are inherent in its retrospective 
design, making it therefore necessarily complicated by 
lead-time and length-time biases. In this study, pathological 
diagnosis in almost all of our patients was obtained using 
transbronchial biopsy specimens. Therefore, patients whose 
pulmonary functional impairment was too severe to permit 
carrying out diagnostic procedures might have been excluded, 
and only selected SCLC patients with ILD deemed able to tolerate 
these procedures were included. Another limitation is the lack 
of information about the assessment of respiratory function and 
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precise pathological diagnosis of ILD. Randomized, prospective 
studies comparing prognosis in SCLC patients with or without 
ILD are the only way to obtain an unconfounded estimate of the 
prognostic effect of ILD. However, we recognize that it has some 
clinical importance for the management of future patients of 
unselected groups. Our results apparently showed that the 
therapeutic approach is complicated when SCLC patients have ILD. 
Our results imply that existing ILD does adversely affect the 
outcome of SCLC. When deciding whether to offer an intensive 
therapy that may increase treatment-related mortality, the 
individual patient’s medical condition, including coexistence 
of ILD, should be taken into consideration, although favorable 
results have been reported in a small number of patients with 
ILD.6,7,13 Therefore, detailed history taking and physical 
examination are required to elucidate the presence of signs 
and/or symptoms of ILD.  
In summary, chest CT scan is indicated not only to evaluate 
metastatic lesions from SCLC but also to detect ILD. Appropriate 
pre-evaluation for the indication of standard therapy or 
adequate palliative care is essential to provide prolonged 
quality survival, which is the primary goal of therapy for SCLC 
patients with ILD. 
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Figure legend 
 
Figure 1. Survival curves of the 2 groups of SCLC patients with 
or without interstitial lung disease (ILD). The upper line is 
the survival curve of patients without ILD; the lower line is 
the curve of patients with ILD. 
 
 
Table 1. Characteristics of patients with small cell lung cancer 
                                                                       
No. of patients 332 
 
Age (year) median: 70  range: 27 - 86 
 
Sex 
 Male 294 (88.6%) 
 Female 38 (11.4%) 
 
Performance status 
 0-1 278 (83.7%) 
 2-4 54 (16.3%) 
 
Interstitial pneumonia 
 present 15 (4.5%) 
 absent 317 (95.5%) 
 
Stage  
 Limited  159 (47.9%) 
 Extensive 173 (52.1%) 
 
Treatment 
 Chemotherapy 276 (83.1%) 
 Others 56 (16.9%) 
 
 
Table 2. Differences between SCLC patients with ILD and those without ILD.  
 
 
       Patients with ILD     Patients without ILD           P-value 
       
  Age     
    median, range (years) 68, 58-80 70, 27-86  0.489 
  Sex     
    Male 14 280   
    Female 1 37  0.999 
  Performance status     
    0-1 13 265   
    2-4 2 52  0.999 
  Clinical stage     
    Limited 7 152   
    Extensive 8 165  0.999 
  Treatment     
    Chemotherapy 13 263   
    Surgery + chemotherapy 2 24   
    Chest irradiation 0 25  0.079 
    Supportive care 0 5    
SCLC: small cell lung cancer; ILD: interstitial lung disease 
 
 
 
Table 3. Univariate and multivariate analyses of prognostic factors in 332 patients with small 
cell lung cancer 
 
      Univariate analysis  Multivariate analysis 
 Factors (log-rank test) (Cox`s proportional hazards model) 
  P-value      hazard ratio 95%CI P-value 
 
 
Sex 0.040 0.65 0.44-0.97 0.033 
Stage (limited, extensive) 0.001 0.52 0.39-0.67 0.001 
Performance status (0-1, 2-4) 0.001 0.50 0.36-0.70 0.001 
Interstitial lung disease 0.015 0.43 0.24-0.77 0.005 
Treatment (chemotherapy, others) 0.005 1.45 0.96-2.19 0.077 
 
 
95%CI: 95% confidence interval 
  

